Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings
Introduction Antiretroviral therapy (ART) in resource-limited settings has expanded in the last
decade, reaching> 8 million individuals and reducing AIDS mortality and morbidity …
decade, reaching> 8 million individuals and reducing AIDS mortality and morbidity …
Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis
Background Increased second-line antiretroviral therapy (ART) failure rate narrows future
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …
[HTML][HTML] HIV-positive–to–HIV-positive kidney transplantation—results at 3 to 5 years
Background The outcome of kidney transplantation in human immunodeficiency virus (HIV)–
positive patients who receive organs from HIV-negative donors has been reported to be …
positive patients who receive organs from HIV-negative donors has been reported to be …
Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency …
Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
Interest of youth living with HIV in long-acting antiretrovirals
Objectives: This study's primary objective was to characterize attitudes to long-acting
antiretrovirals (LAARV), among youth aged 13–24 years living with perinatally acquired HIV …
antiretrovirals (LAARV), among youth aged 13–24 years living with perinatally acquired HIV …
Collaborative care for the detection and management of depression among adults receiving antiretroviral therapy in South Africa: study protocol for the CobALT …
L Fairall, I Petersen, B Zani, N Folb, D Georgeu-Pepper… - Trials, 2018 - Springer
Background The scale-up of antiretroviral treatment (ART) programmes has seen HIV/AIDS
transition to a chronic condition characterised by high rates of comorbidity with tuberculosis …
transition to a chronic condition characterised by high rates of comorbidity with tuberculosis …
Intensive adherence counselling for HIV‐infected individuals failing second‐line antiretroviral therapy in Johannesburg, South Africa
Objective In resource‐limited settings, where genotypic drug resistance testing is rarely
performed and poor adherence is the most common reason for treatment failure …
performed and poor adherence is the most common reason for treatment failure …
Multicentre analysis of second‐line antiretroviral treatment in HIV‐infected children: adolescents at high risk of failure
RS Boerma, T Bunupuradah, D Dow… - Journal of the …, 2017 - Wiley Online Library
Introduction: The number of HIV‐infected children and adolescents requiring second‐line
antiretroviral treatment (ART) is increasing in low‐and middle‐income countries (LMIC) …
antiretroviral treatment (ART) is increasing in low‐and middle‐income countries (LMIC) …
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised …
R Gross, J Ritz, MD Hughes, R Salata… - The Lancet Digital …, 2019 - thelancet.com
Background Antiretroviral therapy (ART) non-adherence causes HIV treatment failure. Past
behaviour might predict future behaviour; failing second-line ART could indicate ongoing …
behaviour might predict future behaviour; failing second-line ART could indicate ongoing …
Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
A Häggblom, V Svedhem, K Singh, A Sönnerborg… - The lancet HIV, 2016 - thelancet.com
Background People with HIV-1 in low-income and middle-income countries increasingly
need second-line regimens with boosted protease inhibitors. However, data are scarce for …
need second-line regimens with boosted protease inhibitors. However, data are scarce for …